Your Biopharma Data Needs a Strategy
In the not-so-distant past, physician prescribing data was essentially a…
Success in Rare Disease: Patient Involvement Matters!
This past December, the FDA finalized its guidance on rare diseases with the…
Juggling Geographic Commercialization Priorities
Commercializing a pharmaceutical asset in one country is hard enough. Doing it…
Happy Anniversary to Us!
I grew up in the Midwest — the middle child in a large family. We were each…
Forecasting Models: It’s Not All About the Numbers
What is the difference between strategic thinking in quantifying the future and Excel gymnastics? This was a distinction I needed to learn in my…
Appreciation for Interconnectedness
It was March 2020 when I wrote the first sentences of issue #30 of this e-conversation. At the time, I acknowledged the WHO’s declaration that…
Finding Partners in Biopharma: Standing Out in a Field of Many
When biopharma executives or business development leaders think about developing their “partnering story,” the focus is often on the innovation.…
Gaining Participation in Clinical Trials
When it comes to patient recruitment and retention for clinical trials, the bottom line is simply this: It is important and challenging in all…
Reboot the “Get Organized” Ideas
Last week, The NemetzGroup team met (virtually, of course!) to share insights from 2021 and how we could make 2022 even better. We broke into small…
